The results of vedolizumab CLL covariate analyses were consistent with previous reports (12) and showed a trend for body weight and serum albumin to affect CLL, although the difference only reached clinical relevance (± 25%) at the lowest albumin concentration. This evidence concerns the gene ALB and B-cell chronic lymphocytic leukemia.